Why Amylyx is pulling ALS drug Relyvrio from US market after study
WASHINGTON (AP) — The maker of a drug for Lou Gehrig’s disease that recently failed in a large study said Thursday it will pull the medicine from the market, acknowledging it didn’t help patients with the deadly neurological condition.
Amylyx Pharmaceuticals announced it will voluntarily halt sales and marketing of the drug in the U.S. and Canada, where new patients will no longer be able to get a prescription.
“While this is a difficult moment for the ALS community, we reached this path forward in partnership with the stakeholders who will be impacted and in line with our steadfast commitment to people living with ALS,” company co-founders said in a statement. Patients already taking the therapy who wish to continue will be able to enroll in a program to receive it for free.
The Food and Drug Administration approved the much-debated drug, Relyvrio, in September 2022, following a years-long advocacy campaign by patients with amyotrophic lateral sclerosis, or ALS.
Related articles
The unstoppable duo of Emma Stone and Yorgos Lanthimos
CANNES, France (AP) — Before a journalist has even lobbed a question, Emma Stone and Yorgos Lanthimo2024-05-21Forget the World Cup, Euros or Super Bowl
It took some time to come down from Tuesday night. To actually remember the details of one of those2024-05-21What kind of cancer did O.J. Simpson die from?
CBS News Los Angeles Live2024-05-21Kyle Richards rocks a tuxedo while ex
The Real Housewives Of Beverly Hills were out in force on Wednesday night when several of the realit2024-05-21- Tom Holland enjoyed a post-show cup of tea and proudly waved to fans as he left the Duke of York's T2024-05-21
Ai Weiwei launches new exhibit, says still trying to understand studio demolitions
By Anna Cuenca Dissident artist Ai Weiwei on Monday said the Chinese state’s razing of his stu2024-05-21
atest comment